{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.2","upperLimit":"67.2","value":"57.4"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"41.4","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Intracranial Clinical Benefit Rate (CBR) is defined as the percentage of all treated participants whose best overall response is either a complete response (CR) or partial response (PR) or whose best overall response was Stable Disease (SD) with duration of \\>6 months, as determined by modified RECIST 1.1 criteria for index intracranial lesions based on investigator review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Asymptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Symptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Up to 66 months","title":"Intracranial Clinical Benefit Rate (CBR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}